Last updated: February 15, 2026
What is the current market status for NDC 73070-0403?
NDC 73070-0403 refers to a specific drug product, typically a medication approved by the FDA. To date, this NDC is associated with Aflibercept injection, marketed under the brand names Eylea (by Regeneron Pharmaceuticals). Eylea is used primarily for treating neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal diseases.
The drug's market has expanded consistently since its approval, owing to its widespread adoption in ophthalmology and favorable efficacy profile. Competitive market entry includes biosimilars, which are under development but have yet to achieve significant market penetration.
How does the market landscape look for aflibercept (Eylea)?
Market Size and Growth
- The global ophthalmic drugs market was valued at approximately USD 17 billion in 2021.
- The anti-VEGF segment, including aflibercept, held an estimated USD 4.2 billion share in 2021, growing annually at around 6-8% (reference: MarketsandMarkets, 2022).
Key Market Drivers
- Aging population increasing prevalence of AMD, DME, retinal vein occlusion.
- Expanding indication approvals for aflibercept.
- Competition from alternatives such as ranibizumab (Lucentis) and newer agents like brolucizumab (Beovu).
Market Challenges
- High cost of treatment—annual therapy cost typically ranges USD 2,000–USD 3,500 per injection, with multiple injections annually.
- Patent protections still active until 2024 at least, limiting biosimilar competition.
Price projections for NDC 73070-0403
Current Pricing
- Average wholesale price (AWP): Approximately USD 1,200–USD 1,500 per 4-mg vial, depending on purchase volume and location.
- Actual transaction prices are often lower, owing to rebates, discounts, and negotiated contracts.
Short-Term Trends (Next 1-2 Years)
- No major price reductions expected, given the lack of biosimilar competition and consistent demand.
- Slight downward pressure possible due to market saturation and payer negotiations.
Long-Term Price Outlook (3-5 Years)
- Likely stabilization of prices with minimal reductions.
- Introduction of biosimilars could trigger price erosion, but such products face regulatory, clinical, and market hurdles.
Impact of Biosimilar Development
- Biosimilars for aflibercept are in clinical development phases, with some entering phase 3 trials (e.g., Coherus Biosciences' candidate).
- Approval and market entry anticipated post-2024, which could lead to a 30-50% price reduction in the subsequent years.
Regulatory and Policy Influence
- US patent expiry in 2024 (subject to patent challenges and legal disputes).
- CMS and private insurers are increasingly scrutinizing high-cost biologics, possibly promoting price negotiation strategies.
Competitive Analysis
| Competitor |
Indication |
Market Share (2022) |
Pricing (USD per injection) |
Status |
| Eylea (Aflibercept) |
AMD, DME, RVO |
70% |
1,200–1,500 |
Dominant |
| Lucentis (Ranibizumab) |
AMD, DME |
20-25% |
1,200–1,600 |
Major player |
| Beovu (Brolucizumab) |
AMD |
<5% |
1,500 |
Growing |
Key Takeaways
- Market size for aflibercept remains robust, driven by chronic retinal conditions.
- Pricing has stabilized, with minor fluctuations influenced by payer negotiations and potential biosimilar entry.
- Long-term price reductions hinge on biosimilar approvals, anticipated after 2024, with potential for up to 50% decrease.
- The competitive landscape favors Eylea currently, but biosimilars could disrupt market dynamics.
FAQs
1. What is the primary indication for NDC 73070-0403?
Treatments involving this NDC target age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
2. Are biosimilars expected to impact price in the near term?
Biosimilars are in late-phase clinical development and could enter the market after patent expiry in 2024. Their entry is expected to reduce prices significantly in subsequent years.
3. How does the price of aflibercept compare to alternatives?
Aflibercept’s price per injection is comparable to ranibizumab but generally higher than off-label use of bevacizumab, which is significantly cheaper but less approved for certain uses.
4. What factors could influence price changes besides biosimilar entry?
Market penetration, rebates, insurer negotiations, regulatory changes, and new clinical guidelines could all influence future prices.
5. What is the outlook for the global market?
Growth depends on increased prevalence, device innovations, and regulatory approvals in emerging economies, where market penetration for high-cost biologics remains limited.
Sources
[1] MarketsandMarkets. Ophthalmic Drugs Market, 2022.
[2] FDA Labeling for Eylea (Aflibercept).
[3] IQVIA Data, 2022.
[4] Patent and Regulatory Filings for Biosimilars.
[5] Pharmaceutical pricing databases.
